|
Sex
|
|
Male
|
22 (44%)
|
|
Female
|
28 (56%)
|
|
Age (years) (mean ± SD)
|
48 ± 9.7
|
|
Migrational background
|
|
Dutch / WE
|
4 (8%)
|
|
EE/EA
|
12 (24%)
|
|
NA
|
2 (4%)
|
|
SSA
|
7 (14%)
|
|
SEA
|
23 (46%)
|
|
LA
|
2 (4%)
|
|
ALT (U/l) (mean + SD) combined with HBV DNA levels (IU/mL)
|
|
Normal (0-34 U/l) and HBV DNA < 2.0 · 104
|
44 (88%)
|
|
ALT >1xULN and HBV DNA < 2.0 · 104
|
3 (6%)
|
|
ALT >1xULN and HBV DNA > 2,0 · 104
|
3 (6%)
|
|
Fibrosis stage
|
|
Unknown
|
2 (4%)
|
|
F0-F1
|
45 (90%)
|
|
F2-F3
|
3 (6%)
|
|
Management advice
|
|
No Follow-up needed
|
3 (6%)
|
|
ALT levels every 6-12 months
|
25 (50%)
|
|
ALT levels and HCC screening every 6-12 months
|
14 (28%)
|
|
Strict follow-up every 3-6 months
|
5 (10%)
|
|
Antiviral therapy
|
3 (6%)
|
